Company Overview of Enumeral Biomedical Holdings, Inc.
Enumeral Biomedical Holdings, Inc. discovers and develops novel antibody immunotherapies that help the immune system attack diseased cells. It is developing a pipeline of immunomodulators for the treatment of cancer and inflammatory diseases. The company has collaborations with Sanofi US Services, Inc.; Crucell Holland B.V.; Anthrogenesis Corporation d/b/a Celgene Cellular Therapeutics; and Novartis Pharma AG. Enumeral Biomedical Holdings, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.
One Kendall Square
Cambridge, MA 02139
Founded in 2009
Key Executives for Enumeral Biomedical Holdings, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $250.0K
Co-Founder and Executive Chairman
Total Annual Compensation: $200.0K
Vice President of Business Development and Secretary
Total Annual Compensation: $171.3K
Compensation as of Fiscal Year 2013.
Enumeral Biomedical Holdings, Inc. Key Developments
Enumeral Biomedical Holdings Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014
Mar 19 15
Enumeral Biomedical Holdings Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported revenue of $42,904 compared to $107,991 for the comparable period in 2013. Net income was $3.0 million compared to a net loss of $1.2 million for the comparable period in 2013. Loss from operations was $2,006,746 against $1,145,205 a year ago. Net income before income taxes was $3,040,987 against net loss before income taxes of $1,174,040 a year ago. Basic and diluted earnings per share were $0.06 against basic and diluted loss per share of $0.07 a year ago.
For the year, the company reported revenue of $164,026 for year ended December 31, 2014, compared to $449,036 for the year ended December 31, 2013. These decreases are due to the conclusion of certain collaboration and grant projects in 2013. Net loss was $8.2 million compared to a net loss of $3.9 million for the year ended December 31, 2013. Loss from operations was $6,430,770 against $3,752,466 a year ago. Net loss before income taxes was $8,179,410 against $3,864,589 a year ago. Basic and diluted loss per share was $0.26 against $0.28 a year ago.
Enumeral Biomedical Holdings, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 04:00 PM
Mar 17 15
Enumeral Biomedical Holdings, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 04:00 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: Arthur Tinkelenberg, Co-Founder, Chief Executive Officer, President and Director.
Enumeral Biomedical Holdings, Inc. Announces Partnership Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University to Research Human Mucosal Immunology with Immune Profiling System
Mar 9 15
Enumeral Biomedical Holdings, Inc. announced that the company signed an agreement with the Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard University as part of Enumeral’s Phase II Small Business Innovation Research (SBIR) contract with the National Cancer Institute (NCI). Enumeral is developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which will be deployed in the laboratory of Douglas S. Kwon, M.D., Ph.D., Assistant Professor of Medicine at the Ragon Institute. Enumeral recently announced an agreement to place the system with Memorial Sloan-Kettering Cancer Center. Dr. Kwon’s research focuses on the immunology of mucosal surfaces and tissues, which are home to between 60 and 90% of the body’s lymphocytes, which are primary disease-fighting white blood cells. Studying these immunological compartments in human patients relies on “small volume” clinical specimens such as core biopsy, which often contain limited numbers of cells and can be challenging to analyze with conventional technologies. Enumeral’s collaboration with the Ragon Institute is supported by a Phase II SBIR contract from the NCI for $999,967 over two years. The NCI is funding the entirety of the program, which complements Enumeral’s other internal research and development efforts. Enumeral generated proof of concept in this area under a Phase I contract in 2012 and 2013. News Source: Partnership to Research Human Mucosal Immunology with Immune Profiling System.
Similar Private Companies By Industry
Recent Private Companies Transactions